MarketCapExport financials
Kazia Therapeutics Limited (KZIA)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Kazia Therapeutics Limited Balance Sheet 2025-2011 | KZIA
Brief overview of Kazia Therapeutics Limited's balance sheet strength
The balance sheet is assessed across five available annual reports spanning 2021 to 2025.
Assets fell from 57.1 million AUD to 6.1 million AUD. This may reflect either deliberate optimization or a reduction in business scale.
Liabilities expanded faster than the asset base, -25.4% versus -89.4%. Debt-service capacity deserves attention.
The cash reserve occupies 71.7% of the balance sheet, previously 48.3%. It is one marker of short-term resilience.
Retained earnings remain negative at -134.8 million AUD. This may reflect past losses or substantial shareholder distributions, so earnings and buybacks provide important context.
Overall picture
Kazia Therapeutics Limited's financial structure calls for caution. Stronger equity, lower debt or restored liquidity would be needed to improve it.
Annual Balance Sheet Kazia Therapeutics Limited
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | - | - | - | - | - | -5.43 M | -5.87 M | -14.4 M | -33.4 M | -44.4 M | 205 K | -1.32 M | - | - |
Long Term Debt Current |
- | - | - | - | - | - | - | 84 K | 10 K | - | - | - | - | - | - |
Total Non Current Liabilities |
309 K | 5.8 M | 8.47 M | 10.9 M | 13.3 M | 3.87 M | 5.08 M | 5.05 M | 5.19 M | 154 K | - | - | - | 7 K | 104 K |
Total Liabilities |
14.4 M | 31.6 M | 16 M | 17.6 M | 19.2 M | 8.94 M | 6.98 M | 8.93 M | 10.6 M | 1.59 M | 1.78 M | 3.25 M | 1.71 M | 3.87 M | 8.31 M |
Deferred Revenue |
- | - | - | - | - | - | - | 138 K | 41 K | - | - | - | - | 1.08 M | 2.14 M |
Retained Earnings |
-135 M | -115 M | -89.1 M | -68.6 M | -44.2 M | -36.2 M | -24.9 M | -14.6 M | -171 M | -161 M | -148 M | -141 M | -134 M | -192 M | -187 M |
Total Assets |
6.06 M | 21.6 M | 28.1 M | 35.9 M | 57.1 M | 23.1 M | 21.2 M | 28.2 M | 35.9 M | 35.5 M | 46.1 M | 4.66 M | 5.75 M | 8.98 M | 12.7 M |
Cash and Cash Equivalents |
4.34 M | 1.66 M | 5.24 M | 7.36 M | 27.6 M | 8.76 M | 5.43 M | 5.96 M | 14.5 M | 33.5 M | - | - | - | - | - |
Book Value |
-8.3 M | -10 M | 12 M | 18.3 M | 37.9 M | 14.1 M | 14.2 M | 19.2 M | 25.3 M | 33.9 M | 44.4 M | 1.41 M | 4.04 M | 5.11 M | 4.42 M |
Total Shareholders Equity |
- | - | 12 M | 18.3 M | 37.9 M | 14.1 M | 14.2 M | 19.2 M | 25.3 M | 33.9 M | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in AUD currency
Quarterly Balance Sheet Kazia Therapeutics Limited
| 2026-Q2 | 2025-Q4 | 2025-Q2 | 2024-Q4 | 2024-Q2 | 2023-Q4 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Non Current Liabilities |
272 K | 5.8 M | 5.21 M | 8.47 M | 5.8 M | 13.3 M | 8.47 M | - | - | - | - | - | - | 11.9 M | - | - | - | 3.87 M | - | - | - | 5.08 M | - | - | - | 5.05 M | - | - | - | 5.19 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
24.6 M | 31.6 M | 21.7 M | 16 M | 31.6 M | 19.2 M | 16 M | - | - | - | - | - | - | 20.2 M | - | - | - | 8.94 M | - | - | - | 6.98 M | - | - | - | 8.93 M | - | - | - | 10.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-146 M | -115 M | -125 M | -89.1 M | -115 M | -44.2 M | -89.1 M | - | - | - | - | - | - | -44.2 M | - | - | - | -36.2 M | - | - | - | -24.9 M | - | - | - | -14.6 M | - | - | - | -171 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
71.1 M | 21.6 M | 17.9 M | 28.1 M | 21.6 M | 57.1 M | 28.1 M | - | - | - | - | - | - | 58.1 M | - | - | - | 23.1 M | - | - | - | 21.2 M | - | - | - | 28.2 M | - | - | - | 35.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
69.5 M | 7.36 M | 3.06 M | 5.24 M | 1.66 M | 7.36 M | 5.24 M | - | - | - | - | - | - | 27.6 M | - | - | - | 8.76 M | - | - | - | 5.43 M | - | - | - | 5.96 M | - | - | - | 14.5 M | - | - | - | 33.5 M | - | - | - | 44.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
46.5 M | -10 M | -3.81 M | 12 M | -10 M | 37.9 M | 12 M | - | - | - | - | - | - | 37.9 M | - | - | - | 14.1 M | - | - | - | 14.2 M | - | - | - | 19.2 M | - | - | - | 25.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
46.5 M | - | -3.81 M | - | 5.27 M | 14.1 M | 12 M | - | - | - | - | - | - | 37.9 M | - | - | - | 14.1 M | - | - | - | 14.2 M | - | - | - | 19.2 M | - | - | - | 25.3 M | - | - | - | 33.9 M | - | - | - | 44.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in AUD currency
Balance Sheet is a fundamental financial report of Kazia Therapeutics Limited, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Biotechnology
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Moderna
MRNA
|
$ 245.81 | 1.54 % | $ 95.6 B |  USA |
 |
InMed Pharmaceuticals
INM
|
$ 1.36 | 1.49 % | $ 5.66 M |  Canada |
 |
INmune Bio
INMB
|
$ 1.61 | 0.62 % | $ 39.9 M | USA |
 |
Novo Nordisk A/S
NVO
|
$ 39.06 | -0.71 % | $ 174 B |  Danmark |
 |
Inovio Pharmaceuticals
INO
|
$ 0.8 | -21.26 % | $ 37.5 M | USA |
 |
Insmed Incorporated
INSM
|
$ 94.04 | -1.7 % | $ 18.7 B | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$ 11.75 | -0.51 % | $ 760 M | USA |
 |
Biogen
BIIB
|
$ 240.98 | -0.87 % | $ 35.3 B | USA |
 |
BioVie
BIVI
|
$ 1.26 | 1.61 % | $ 1.86 M | USA |
 |
Ionis Pharmaceuticals
IONS
|
$ 44.27 | -2.49 % | $ 7.08 B | USA |
 |
Innate Pharma S.A.
IPHA
|
$ 1.57 | -0.51 % | $ 141 M |  France |
 |
NextCure
NXTC
|
$ 5.42 | -0.46 % | $ 15.4 M | USA |
 |
BeyondSpring
BYSI
|
$ 0.5 | -5.13 % | $ 20.6 M | USA |
 |
Capricor Therapeutics
CAPR
|
$ 5.88 | -11.04 % | $ 273 M | USA |
 |
Vaxcyte
PCVX
|
$ 63.23 | -4.53 % | $ 8.6 B | USA |
 |
Oncolytics Biotech
ONCY
|
$ 0.51 | 2.57 % | $ 48.9 M | Canada |
 |
Outlook Therapeutics
OTLK
|
$ 0.56 | 7.94 % | $ 19.5 M | USA |
 |
Wave Life Sciences Ltd.
WVE
|
$ 3.37 | -1.46 % | $ 568 M |  Singapore |
 |
Passage Bio
PASG
|
$ 3.59 | -0.28 % | $ 11.5 M | USA |
 |
Forte Biosciences
FBRX
|
$ 76.99 | 0.03 % | $ 997 M | USA |
 |
Mirum Pharmaceuticals
MIRM
|
$ 83.44 | -1.92 % | $ 4.19 B | USA |
 |
Inhibikase Therapeutics
IKT
|
$ 1.66 | -2.92 % | $ 163 M | USA |
|
Immatics N.V.
IMTX
|
$ 7.69 | 2.4 % | $ 941 M |  Germany |
 |
Immunic
IMUX
|
$ 7.48 | 0.94 % | $ 1.16 B | USA |
 |
Immunovant
IMVT
|
$ 28.38 | -0.73 % | $ 5.18 B | USA |
 |
MediciNova
MNOV
|
$ 1.41 | 3.68 % | $ 69.2 M | USA |
 |
Iovance Biotherapeutics
IOVA
|
$ 14.62 | -1.62 % | $ 5.22 M | USA |
|
Rezolute
RZLT
|
$ 3.7 | -1.22 % | $ 384 M | USA |
 |
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M | Canada |
 |
Krystal Biotech
KRYS
|
$ 322.17 | -1.0 % | $ 9.32 B | USA |
 |
Nektar Therapeutics
NKTR
|
$ 38.27 | -2.42 % | $ 646 M | USA |
 |
NanoViricides
NNVC
|
$ 1.51 | 0.67 % | $ 30.5 M | USA |
 |
Grifols, S.A.
GRFS
|
$ 7.5 | -0.53 % | $ 5.1 B |  Spain |
 |
Tarsus Pharmaceuticals
TARS
|
$ 70.5 | -0.75 % | $ 2.95 B | USA |
 |
Nurix Therapeutics
NRIX
|
$ 26.02 | -0.31 % | $ 2.26 B | USA |
 |
Savara
SVRA
|
$ 4.67 | -1.89 % | $ 1.04 B | USA |
 |
Ocugen
OCGN
|
$ 0.82 | 0.32 % | $ 256 M | USA |
 |
Oragenics
OGEN
|
$ 0.41 | -4.91 % | $ 884 K | USA |
 |
Omeros Corporation
OMER
|
$ 16.26 | -1.75 % | $ 1.03 B | USA |
 |
Xenetic Biosciences
XBIO
|
$ 2.02 | 1.0 % | $ 3.44 M | USA |
|
XBiotech
XBIT
|
$ 1.99 | -1.49 % | $ 60.7 M | USA |
 |
ORIC Pharmaceuticals
ORIC
|
$ 13.85 | 0.51 % | $ 1.22 B | USA |
 |
Aligos Therapeutics
ALGS
|
$ 4.96 | -1.39 % | $ 49 M | USA |
 |
Alkermes plc
ALKS
|
$ 43.48 | -1.43 % | $ 7.16 B |  Irlanda |
 |
Jazz Pharmaceuticals plc
JAZZ
|
$ 211.97 | -0.84 % | $ 12.9 B | Irlanda |
 |
Xenon Pharmaceuticals
XENE
|
$ 35.95 | -0.88 % | $ 2.85 B | Canada |
 |
Xeris Pharmaceuticals
XERS
|
$ 10.79 | -3.1 % | $ 1.73 B | USA |
 |
Phio Pharmaceuticals Corp.
PHIO
|
$ 0.89 | 0.31 % | $ 5.33 M | USA |
 |
Kymera Therapeutics
KYMR
|
$ 112.63 | -0.73 % | $ 9.52 B | USA |
 |
Praxis Precision Medicines
PRAX
|
$ 256.47 | -3.03 % | $ 5.77 B | USA |